�����ƽ��

In drug discovery, muscle tissues are evaluated for both target-specific efficacy and off-target toxicity. Cardiotoxicity remains a major development risk across therapeutic classes, while skeletal muscle can be affected by metabolic, inflammatory, or neuromuscular side effects. Human induced pluripotent stem cell (iPSC)-derived skeletal and cardiac muscle models allow you to measure functional contractility, electrophysiological properties, structural organization, and cellular stress responses. Use these physiologically-relevant human muscle models to identify cardiac liabilities earlier, investigate mechanisms of muscle-related toxicity, and support the development and implementation of new approach methodologies (NAMs).

Muscle models can also advance translational research and disease modeling. Study muscular dystrophies, cardiomyopathies, and other muscle disorders, for target validation and biomarker discovery through quantitative assessment of contractile performance and cellular health. By incorporating human muscle platforms into your development workflows, you strengthen safety evaluation and improve confidence in candidate selection.

Explore in vitro muscular system tools for your NAM development.